Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Maurizio Brausi, Jorg Oddens, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)69-76
JournalEuropean Urology
Issue number1
Publication statusPublished - Jan 2014


  • Urothelial carcinoma
  • Non-muscle-invasive bladder cancer
  • Maintenance BCG
  • Dose reduction
  • Side effects

Cite this